Mette Thorn - ExpreS2ion Biotech VP Devel

All Insiders . Sweden . 
Stock . ExpreS2ion Biotech Holding . Stakeholders . Insider . Mette Thorn
EXPRS2 Stock  SEK 18.68  0.06  0.32%   

Insider

Mette Thorn is VP Devel of ExpreS2ion Biotech Holding
Phone45 22 22 10 19
Webhttps://www.expres2ionbio.com

ExpreS2ion Biotech Management Efficiency

The company has return on total asset (ROA) of (0.5513) % which means that it has lost $0.5513 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.9735) %, meaning that it generated substantial loss on money invested by shareholders. ExpreS2ion Biotech's management efficiency ratios could be used to measure how well ExpreS2ion Biotech manages its routine affairs as well as how well it operates its assets and liabilities.
ExpreS2ion Biotech Holding has accumulated 3.48 M in total debt with debt to equity ratio (D/E) of 10.4, indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. ExpreS2ion Biotech has a current ratio of 2.57, suggesting that it is liquid and has the ability to pay its financial obligations in time and when they become due. Debt can assist ExpreS2ion Biotech until it has trouble settling it off, either with new capital or with free cash flow. So, ExpreS2ion Biotech's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like ExpreS2ion Biotech sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for ExpreS2ion to invest in growth at high rates of return. When we think about ExpreS2ion Biotech's use of debt, we should always consider it together with cash and equity.

Similar Executives

Showing other executives

INSIDER Age

Oskar BossonBioArctic AB
47
Pr LannfeltBioArctic AB
74
Anne LannerHansa Biopharma AB
54
Gunilla OsswaldBioArctic AB
62
Sren MScHansa Biopharma AB
58
Nina IversXbrane Biopharma AB
53
Associate GierXbrane Biopharma AB
N/A
Harald BorgekeBioArctic AB
N/A
Klaus SindahlHansa Biopharma AB
N/A
Pr GellerforsBioArctic AB
76
Johanna FltingBioArctic AB
51
Maria EdebrinkXbrane Biopharma AB
54
Samuel WagnerXbrane Biopharma AB
N/A
Martin markXbrane Biopharma AB
43
Christer MllerBioArctic AB
64
Frida LekanderBioArctic AB
N/A
Anette LindqvistXbrane Biopharma AB
57
Erik DominesXbrane Biopharma AB
59
Katja MargellHansa Biopharma AB
N/A
Emanuel BjrneHansa Biopharma AB
50
David VikstrmXbrane Biopharma AB
46
ExpreS2ion Biotech Holding AB , through its subsidiary, ExpreS2 ion Biotechnologies ApS, develops a platform technology that enables the production of complex proteins for new vaccines and diagnostics of malaria. ExpreS2ion Biotech Holding AB is based in Horsholm, Denmark. ExpreS2ion Biotech operates under Biotechnology classification in Sweden and is traded on Stockholm Stock Exchange. It employs 15 people. ExpreS2ion Biotech Holding (EXPRS2) is traded on Stockholm Exchange in Sweden and employs 14 people.

Management Performance

Return On Equity-0.97
Return On Asset-0.55

ExpreS2ion Biotech Leadership Team

Elected by the shareholders, the ExpreS2ion Biotech's board of directors comprises two types of representatives: ExpreS2ion Biotech inside directors who are chosen from within the company, and outside directors, selected externally and held independent of ExpreS2ion. The board's role is to monitor ExpreS2ion Biotech's management team and ensure that shareholders' interests are well served. ExpreS2ion Biotech's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, ExpreS2ion Biotech's outside directors are responsible for providing unbiased perspectives on the board's policies.
Keith Alexander, Chief Officer
Lars Petersen, Medical Oncology
Mette Thorn, VP Devel
Bent MSc, Chief Officer
Mattis Ranthe, Chief Officer
Max Sogaard, Dev Research

ExpreS2ion Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is ExpreS2ion Biotech a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Equity-0.97
Return On Asset-0.55
Operating Margin(20.75) %
Current Valuation361.15 M
Shares Outstanding37.15 M
Shares Owned By Institutions1.75 %
Price To Book3.42 X
Price To Sales55.94 X
Revenue12.23 M
Gross Profit1.07 M

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Other Information on Investing in ExpreS2ion Stock

ExpreS2ion Biotech financial ratios help investors to determine whether ExpreS2ion Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in ExpreS2ion with respect to the benefits of owning ExpreS2ion Biotech security.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY